The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay
Histone deacetylase 3 (HDAC3) is a potential target for the treatment of human diseases such as cancers, diabetes, chronic inflammation and neurodegenerative diseases. Previously, we proposed a virtual screening (VS) pipeline named "Hypo1_FRED_SAHA-3" for the discovery of HDAC3 inhibitors...
Saved in:
Main Authors: | Jie Xia (Author), Huabin Hu (Author), Wenjie Xue (Author), Xiang Simon Wang (Author), Song Wu (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2018-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bioassay-guided discovery of antibacterial agents: in vitro screening of Peperomia vulcanica, Peperomia fernandopoioana and Scleria striatinux
by: Mbah James A, et al.
Published: (2012) -
Discovery of potential WEE1 inhibitors via hybrid virtual screening
by: Tingting Jin, et al.
Published: (2023) -
Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening
by: Noor Atatreh, et al.
Published: (2019) -
Discovery of a Novel and Potent Dual-Targeting Inhibitor of ATM and HDAC2 Through Structure-Based Virtual Screening for the Treatment of Testicular Cancer
by: Ruan Y, et al.
Published: (2024) -
Discovery of Indole-Containing Benzamide Derivatives as HDAC1 Inhibitors with In Vitro and In Vivo Antitumor Activities
by: Xiu Gu, et al.
Published: (2022)